References

Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review

10.3389/fmicb.2019.00539 · 2019 · External reference

Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis

10.1093/jac/dkac145 · 2022 · External reference

Pharmacokinetics/Pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa

10.1128/aac.00126-11 · 2011 · External reference

Tolerance and resistance of biofilm infections

10.1038/s41579-022-00682-4 · 2022 · External reference

10.7554/elife.65836.sa2

10.7554/elife.65836.sa2 · External reference

Genetic and functional diversity of Psseudomonas aeruginosa lipololysaccharide

10.3389/fmicb.2011.00118 · 2011 · External reference

Rescuing the last-line polymyxins: Achievement and challenges

10.1124/pharmrev.120.000020 · 2021 · External reference

PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients

10.1128/aac.05391-11 · 2011 · External reference

PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients

10.1128/aac.05829-11 · 2012 · External reference

Polymyxin resistance of Pseudomonas phoQ mutants is dependent on additional two-component regulatory systems

10.1128/aac.02353-12 · 2012 · External reference

The role of the cell envelope in resistance

1975 · External reference

Adaptive resistance to polymyxin in Pseudomonas aeruginosa due to an outer membrane impermeability mechanism

10.1139/m82-125 · 1982 · External reference

Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa

10.1046/j.1365-2958.2003.03673.x · 2003 · External reference

Adaptive resistance to the “last hope” antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-compartment regulatory system ParR-ParS

10.1128/aac.00242-10 · 2010 · External reference

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

10.1038/35023079 · 2000 · External reference

The metabolically active subpopulation in Pseudomonas aeruginosa aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms

10.1111/j.1574-695x.2012.00929.x · 2012 · External reference

Mechanism and clinical relevance of bacterial heteroresistance

10.1038/s41579-019-0218-1 · 2019 · External reference

Antibiotic combinations that exploit heteroresistance tdo multiple drugs effectively control infection

10.1038/s41564-019-0480-z · 2019 · External reference

Formation of Pseudomonas aeruginosa inhibition zone during disk diffusion is due to transition from planktonic to biofilm mode of growth

10.1016/j.ijantimicag.2018.12.015 · 2019 · External reference

Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumonias, Pseudomonas aeruginosa, and Acinetobacter spp

10.1016/j.cmi.2017.11.020 · 2018 · External reference

Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of sensititre, microscan, vitek 2, and Etest with broth microdilutiuon

10.1128/jcm.00268-17 · 2017 · External reference

Susceptibility testing for the polymyxins: Two steps back, three steps forward?

10.1128/jcm.00888-17 · 2017 · External reference

Plastic binding feature of polymyxins: the effect on MIC susceptibility measurements

10.2147/idr.s219130 · 2019 · External reference

Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia

10.1093/jac/dkq131 · 2010 · External reference

Polymorphonuclear Leukocytes restrict the Growth of Pseudomonas aeruginosa in Lungs of Cystic Fibrosis Patients

10.1128/iai.01969-14 · 2014 · External reference

Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild-type strains in respiratoray infections in patients with cystic fibrosis

10.1128/jcm.33.1.37-40.1995 · 1995 · External reference

Tolerance to the antimicrobial peptide colistin in P. aeruginosa biofilms is linked to metabolic active cells and depends on the pmr-operon and mexAB-oprM

10.1111/j.1365-2958.2008.06152.x · 2008 · External reference

Genome organization in Pseudomonas

10.1146/annurev.mi.40.100186.000455 · 1986 · External reference

Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli

10.1128/jb.62.3.293-300.1951 · 1951 · External reference

Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum

10.3389/fmicb.2014.00554 · 2014 · External reference

Inhibition of Pseudomonas aeruginosa quorum sensing by chemical induction of the MexEF-oprN efflux pump

10.1128/aac.01387-23 · 2024 · External reference

Hackflex: low-cost, highthroughput, illumina nextera flex library construction

2022 · External reference

Twelve years of SAMtools and BCFtools

10.1093/gigascience/giab008 · 2021 · External reference

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3

10.4161/fly.19695 · 2012 · External reference

Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin resistance in clinical isolates of Pseudomonas aeruginosa

10.1128/aac.00893-09 · 2009 · External reference

Calculation of various physics constants in heterogenous substances I. Dielectricity constants and conductivity of mixed bodies from isotropic substances

10.1002/andp.19354160705 · 1935 · External reference

Hindered diffusion in agarose gels: Test of effective medium model

10.1016/s0006-3495(96)79645-5 · 1996 · External reference

The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions

10.1038/ncomms13002 · 2016 · External reference

Antibiotic resistance in P. aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system

10.1128/aac.00428-08 · 2009 · External reference

Colistin is extensively lost during standard in vitro experimental conditions

10.1128/aac.00857-17 · 2017 · External reference

Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infection

10.1002/ppul.24269 · 2019 · External reference

The accessibility of topical treatment in the paranasal sinuses on operated cystic fibrosis patients assessed by scintigraphy

10.4193/rhin17.243 · 2018 · External reference

Stability of colistin and colistin-methanesulfonat in aqueous media and plasma as determined by high-performance liquid chromatography

10.1128/aac.47.4.1364-1370.2003 · 2003 · External reference

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients

10.1016/j.jcf.2008.02.003 · 2008 · External reference

Colistin inhalation therapy in Cystic Fibrosis patients with chronic Pseudomonas aeruginosa lung infection. A prospective double-blind placebo-controlled trial

10.1093/jac/19.6.831 · 1987 · External reference

Prevention of chronic colonization with Pseudomonas aeruginosa in patients with Cystic Fibrosis by early treatment with Ciprofloxacin and inhalation with Colistin

10.1016/0140-6736(91)91446-2 · 1991 · External reference

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

10.1016/j.jcf.2008.06.009 · 2008 · External reference